Andrea Stebel
Hematology & Oncology · Newport Beach, CANPI 1447258389
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $331,791 of the $485,889 with a category attached, or 68.3%. Lilly USA, LLC accounts for 73.2% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $158,786 and has fallen 87.5% since, to $19,892 in 2025. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 987 payments — averaging $492.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$355K
- Bristol Myers Squibb$52K
- Tersera Therapeutics LLC$35K
- Gilead$17K
- Coherus Oncology, Inc.$8K
- AstraZeneca$7K
- plus $11K from 21 others
What the payments were for
- Consulting fees$57,25112%
- Speaking & faculty fees$331,79168%
- Grants$2500%
- Travel & lodging$85,12918%
- Food & beverage$11,4502%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 746 | $355,490 |
| Bristol Myers Squibb | 56 | $51,963 |
| Tersera Therapeutics LLC | 94 | $34,675 |
| Gilead | 26 | $16,941 |
| Coherus Oncology, Inc. | 8 | $8,266 |
| AstraZeneca(2 entities) | 17 | $7,432 |
| Eli Lilly | 4 | $6,500 |
| Puma Biotechnology, Inc. | 1 | $2,180 |
| Daiichi Sankyo Inc. | 3 | $1,198 |
| Cepheid | 2 | $704 |
| Amgen | 4 | $82 |
| Merck | 4 | $71 |
| Exelixis Inc. | 3 | $66 |
| Bayer | 2 | $46 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $29 |
| Novartis | 2 | $29 |
| AbbVie | 2 | $29 |
| Eisai Inc. | 2 | $27 |
| Shire North American Group Inc | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Incyte Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$485,889 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Newport Beach
- Misagh KarimiNewport Beach$782K
- George SemeniukNewport Beach$483K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.